Next Article in Journal
Noninvasive Determination of the IDH Status of Gliomas Using MRI and MRI-Based Radiomics: Impact on Diagnosis and Prognosis
Next Article in Special Issue
Gastrointestinal Stromal Tumours (GIST) of the Rectum: A Systematic Review and Meta-Analysis
Previous Article in Journal
Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
Previous Article in Special Issue
In Silico Identification and Validation of Cuproptosis-Related LncRNA Signature as a Novel Prognostic Model and Immune Function Analysis in Colon Adenocarcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 29
Issue 10
10.3390/curroncol29100541
Review Report
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

The Role of Immunotherapy in Pancreatic Cancer

Curr. Oncol. 2022, 29(10), 6864-6892; https://doi.org/10.3390/curroncol29100541
by Reetu Mukherji 1, Dipanjan Debnath 2, Marion L. Hartley 1 and Marcus S. Noel 1,*
Reviewer 1: Anonymous
Reviewer 2:
Yaqing Qie
Curr. Oncol. 2022, 29(10), 6864-6892; https://doi.org/10.3390/curroncol29100541
Submission received: 15 August 2022 / Revised: 9 September 2022 / Accepted: 15 September 2022 / Published: 23 September 2022
(This article belongs to the Special Issue Immunotherapy for Gastrointestinal Cancer)

Round 1

Reviewer 1 Report

This manuscript thoroughly summarized current immunotherapy in pancreatic cancer treatment from different angles, including immune checkpoint inhibitors, adoptive cellular therapy, and vaccine therapy. The manuscript is well written and easy to follow and understand.

one minor suggestion is in the ICI section, based on the summary by the authors, it seems that PDAC responds less to ICI treatment and the authors explained the mechanisms of immunotherapy resistance, however, the paragraph " mechanisms of immunotherapy resistance" reads relatively isolated. Any failure cases summarized in the ICI section are related to these mechanisms? If any mechanisms of immunotherapy resistance the author introduced can explain the lower response to ICI in PDAC, the author can insert these mechanisms in the paragraphs that introduced the efficacy of ICI monotherapy, dual therapy, and ICI combined with chemotherapy in PDAC to help the readers to understand why PDAC fails to respond to the ICI treatment.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

The authors summarized several immunotherapy approaches in pancreatic cancer including immune checkpoint inhibitor (ICI) related therapy, adaptive cellular therapy as well as vaccine therapy. 

Comments:

1. For CAR-T therapy in pancreatic cancer, any progress in dual-CAR-T therapy? how about the progress for CAR-T therapy combine with other therapies?

2. Are there any connection among these three kind of immunotherapies (ICI, adaptive cellular therapy as well as vaccine therapy in PDAC?

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop